These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 24731854)
1. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis. Link JM; Hurlin PJ Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854 [TBL] [Abstract][Full Text] [Related]
6. Chromatin dynamics at the hTERT promoter during transcriptional activation and repression by c-Myc and Mnt in Xenopus leavis oocytes. Wahlström T; Belikov S; Arsenian Henriksson M Exp Cell Res; 2013 Dec; 319(20):3160-9. PubMed ID: 23860446 [TBL] [Abstract][Full Text] [Related]
9. Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells. Dezfouli S; Bakke A; Huang J; Wynshaw-Boris A; Hurlin PJ Mol Cell Biol; 2006 Mar; 26(6):2080-92. PubMed ID: 16507988 [TBL] [Abstract][Full Text] [Related]
10. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. Diolaiti D; McFerrin L; Carroll PA; Eisenman RN Biochim Biophys Acta; 2015 May; 1849(5):484-500. PubMed ID: 24857747 [TBL] [Abstract][Full Text] [Related]
11. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome. Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671 [TBL] [Abstract][Full Text] [Related]
12. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis. Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211 [TBL] [Abstract][Full Text] [Related]
14. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis. Link JM; Ota S; Zhou ZQ; Daniel CJ; Sears RC; Hurlin PJ Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19685-90. PubMed ID: 23150551 [TBL] [Abstract][Full Text] [Related]
15. Mnt takes control as key regulator of the myc/max/mxd network. Wahlström T; Henriksson M Adv Cancer Res; 2007; 97():61-80. PubMed ID: 17419941 [TBL] [Abstract][Full Text] [Related]
16. Reconstitution of an E box-binding Myc:Max complex with recombinant full-length proteins expressed in Escherichia coli. Farina A; Faiola F; Martinez E Protein Expr Purif; 2004 Apr; 34(2):215-22. PubMed ID: 15003254 [TBL] [Abstract][Full Text] [Related]
17. Mnt: a novel Max-interacting protein and Myc antagonist. Hurlin PJ; Qúeva C; Eisenman RN Curr Top Microbiol Immunol; 1997; 224():115-21. PubMed ID: 9308234 [TBL] [Abstract][Full Text] [Related]
18. Kinetics of myc-max-mad gene expression during hepatocyte proliferation in vivo: Differential regulation of mad family and stress-mediated induction of c-myc. Mauleon I; Lombard MN; Muñoz-Alonso MJ; Cañelles M; Leon J Mol Carcinog; 2004 Feb; 39(2):85-90. PubMed ID: 14750213 [TBL] [Abstract][Full Text] [Related]
19. Switch from Mnt-Max to Myc-Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes. Yang H; Li TW; Ko KS; Xia M; Lu SC Hepatology; 2009 Mar; 49(3):860-70. PubMed ID: 19086036 [TBL] [Abstract][Full Text] [Related]
20. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma. Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096 [No Abstract] [Full Text] [Related] [Next] [New Search]